Kornimate/medical-research-clean huggingface dataset:
metabonomics study of chronic gastritis and gastric carcinoma

Conditions: Gastric Cancer

Summary: the pathogenetic mechanisms of chronic gastritis and gastric carcinoma are different. whether metabonomics play a role in the development of chronic gastritis and gastric cancer is still a question. so the investigators want to clarify this question by this subject.

this project was an untargeted metabolomics study using liquid chromatography coupled with mass spectrometry (lc-ms) in patients with chronic gastritis and gastric carcinoma. the experimental procedures mainly include sample collection, metabolite extraction, lc-ms/ms detection, data analysis, etc.the goal of this study is to identify and (relatively) quantify as many metabolites in biological systems as possible, so as to reveal the overall metabolite information to the maximum extent. metabolomics aims to investigate the changes of metabolites in gastric tissues in patients with chronic gastritis and gastric carcinoma, and to study the biological processes in which these metabolites participate by screening the different metabolites in the different groups, and to reveal the mechanism of life activities in which they involved in.

Eligibility criteria:
inclusion criteria: * patients with chronic superficial gastritis and chronic atrophic gastritis * patients with gastric carcinoma exclusion criteria: * patients with history of surgery * patients with severe heart disease,lung disease or kidney disease.
acute kidney outreach to reduce deterioration and death (akordd)

Conditions: Acute Kidney Injury

Summary: the study pilots an outreach service for acute kidney injury (aki) patients, based on electronic alerts. using the alerts we will contact the primary clinician caring for the patient with aki in the intervention group. the study has a control group of patients receiving good standard care, but without outreach. the aim is to reduce morbidity and mortality in the syndrome, and also to reduce healthcare costs.

lay summary: about one in six hospital inpatients suffer acute kidney injury (aki), also called acute renal failure. about a third of patients with aki die. the large majority of patients with aki are managed by doctors who are not kidney experts. effective aki advice and treatments are available but not currently integrated into routine care. a recent national review of the care of patients who died from aki showed poor management of many patients. early diagnosis of aki can avoid complications, dialysis (which affects the quality of life of patients, and is costly) or death. aki is diagnosed by a change in a blood test. we have developed computer software to diagnose aki earlier. it sends a warning or 'alert' about the test to our team of kidney experts. we will further develop the settings of the alert system. it needs to send an alert for the right patients. we will also study the best way to make clinicians pay attention to their patients who are developing aki. when our expert outreach team receive an alert, they will call the doctor or nurse looking after the patient with aki. we will advise on the best treatment for that patient, to reduce their risk of death, dialysis and other complications. we will do a pilot study in one large hospital, to further develop the system, and check it reduces the risk of death or complications from aki. we will use this work to develop a larger trial of this new system of care for patients with aki in different hospitals. this will convince the wider nhs of the need to change, and show how to prevent or reduce aki. ultimately we aim to improve patients' lives by reducing avoidable death and illness from aki , and also save the nhs money.

Eligibility criteria:
inclusion criteria: * adult patients with an alert for aki issued in accordance with the national algorithm for aki alerts (nhs england) * aki stage 2 or 3 (this criterion is under review during the preparatory phase of the study) exclusion criteria: * patients already on dialysis for aki at the time of alert * patients with end stage renal disease * patients \<18 years of age * patients with no evidence of aki on review of the automated alert * patients dissenting from participation according to the ethics application

Keywords: electronic alerts acute kidney injury nhs mortality
impact of antibiotic treatment of group a streptococcal blistering distal dactylitis in children

Conditions: Blistering Distal Dactylitis

Summary: single-center prospective study to assess the clinical course of group a streptococcal blistering distal dactylitis in children after antibiotic treatment.

blistering distal dactylitis are very common in children. about 60% are caused by staphylococcus aureus and some are caused by group a streptococcus (gas) or streptococcus pyogenes. while these forms have been known for fifty years, few publications are interested in it. some studies have confirmed that a single antibiotic treatment against the sga allows the healing of these dactylitis but few surgical teams have adopted this strategy. as all streptococcal infections, they face the risk of acute complications (septicemia, streptococcal toxic shock, etc.) or late (post-streptococcal glomerulonephritis, acute rheumatic fever, etc.). the involvement of the sga in these dactylitis is easy to demonstrate through the use of rapid gas test already widely used in other gas infections (tonsillitis, scarlet fever, streptococcal perianal infections). this study aims to assess the clinical course of positive gas test blistering distal dactylitis in children after antibiotic treatment.

Eligibility criteria:
inclusion criteria: * children 0-18 years * distal blistering dactylitis collected or not collected * positive rapid group a streptococcus test * informed consent signed by the parents exclusion criteria: * subungual or pulp whitlow * children not affiliated to the social security scheme * refusal by the parents to participate in the study

Keywords: blistering distal dactylitis streptococcus pyogenes antibiotics
evaluating safety and efficacy of fid 112903 post discontinuation of long-term use of restasis® (cyclosporine ophthalmic emulsion) 0.05%

Conditions: Dry Eye Syndrome

Summary: the purpose of this study is to evaluate the safety and efficacy of fid 112903 given as an immediate treatment replacement in dry eye subjects that discontinue at least 6 months use of restasis.


Eligibility criteria:
inclusion criteria: * patients must be at least 18 years of age * patients must have a best corrected visual acuity of 0.6 logmar or better in each eye, and must use restasis bid for at least 6 months. * lastly, patients must have a sodium fluorescein (nafl) corneal staining sum score of greater than or equal to 3 in the worse eye. exclusion criteria: * patients cannot wear contact lenses during the study and cannot have a history of hypersensitivity to any component of fid 112903. * patients cannot have ocular or intraocular surgery or serious ocular trauma within the past 6 months, and cannot have punctal plugs of any type. * patients cannot use any prescription topical medication for other ocular conditions (such as glaucoma, uveitis, etc). * patients cannot use systemic medications that may contribute to dry eye if the dosing regimen has not been stable for at least 30 days prior to visit 1. * patients cannot have ocular conditions that, in the opinion of the investigator, preclude the safe administration of the test article. * patients cannot have a history and/or current evidence of the following: epithelial herpes simplex keratitis (dendritic keratitis); vaccinia, active or recent varicella viral disease of the cornea and/or conjunctiva; active ocular rosacea; acute or chronic bacterial disease of the cornea and/or conjunctiva and/or eyelids; mycobacterial infection of the eye; and/or fungal diseases of the eye.
gathering records to evaluate antiretroviral treatment-south africa

Conditions: HIV

Summary: to achieve global goals for the treatment of hiv, most high-prevalence countries are experimenting with and scaling up differentiated service delivery models (dsd). a handful of efforts have been formally described and evaluated in the literature; many others are being implemented formally or informally under routine care, without a research or evaluation goal. for most countries, however, we have little evidence on the big picture-the proportion of clinics offering alternative models, eligibility criteria and the proportion of patients considered eligible, the number of patients actually participating, health outcomes such as viral suppression, empirical resource utilization compared to traditional care, variations among the models, duration of patient participation, fidelity to model guidelines, effects on clinic efficiency, and sustainability without external donor support. ambit a set of data synthesis, data collection, and data analysis activities aimed at generating information for near- and long-term decision making and creating an approach and platform for ongoing evaluation of differentiated models of hiv treatment delivery in the future. the project will collect and analyze a wide range of existing data sets pertinent to dsd. this protocol is for an analysis of existing medical record data collected by the department of health, implementing partners, and other completed, ongoing, or new evaluations, trials, and observational studies. outcomes to be reported include coverage/uptake of dsd, patients' outcomes, and distribution of each model. there will be no study interaction with individual patients, providers, caregivers, or others for this analysis.


Eligibility criteria:
inclusion criteria: * ≥ 15 years old * patients accessing care for hiv within the data collection period * in any hiv transmission risk group exclusion criteria: * none

Keywords: hiv south africa differentiated service delivery antiretroviral therapy
a study of megestrol acetate in hiv-infected children

Conditions: HIV Infections

Summary: the purpose of this study is to see if megestrol acetate is safe and effective in treating hiv-infected children with failure to thrive (ftt).

the study design is randomized, double-blind, placebo-controlled for 12 weeks with open-label drug offered after week 12.

Eligibility criteria:
inclusion criteria patients must have: * documented hiv infection. * failure to thrive as defined by: * crossing 2 percentile lines on standard weight for age curves over time or less than 5% percentile weight for age and falling from the curve or loss of 10% of baseline body weight. * resistant to oral nutritional supplementation (i.e., ftt despite a minimum 1-month trial of high-calorie oral supplements). * free of significant acute illness (mild upper respiratory tract infections allowed). * patients with chronic diarrhea allowed provided malabsorption and gastrointestinal infection ruled out. exclusion criteria co-existing condition: patients with the following symptoms are excluded: * gastrointestinal infection or malabsorption. * significant acute illness. * any identified, untreated cause for failure to thrive other than underlying hiv infection. * medical contraindications to megestrol acetate. patients with any of the following prior conditions or symptoms are excluded: medical contraindications to megestrol acetate including a history of poorly-controlled hypertension, deep venous thrombosis, or heart failure. history of prior megestrol acetate therapy in the past six months.

Keywords: placebos appetite stimulants megestrol acetate failure to thrive
taf to prevent hbv reactivation in cancer patients

Conditions: Hepatitis B Reactivation

Summary: tenofovir alafenamide (taf) has been approved to prevent hbv reactivation for hbsag-positive cancer patients receiving chemotherapy. however, the real-world effectiveness and safety of taf for cancer patients was lacing. therefore, we conduct a prospective single arm study to evaluate the efficacy and safety of taf as a prophylactic antiviral agent for hbsag-positive cancer patients receiving chemotherapy.

this prospective single arm study would be conducted in taiwan. patients who fulfill the inclusion criteria, will receive taf before the initiation of systemic chemotherapy. based on the guidance of nhi in taiwan, prophylactic anti-viral agent should be prescribed within 7 days before chemotherapy and would be discontinued at 6 months after cessation of chemotherapy. the duration of taf prophylaxis would be followed the guidance of nhi in taiwan, however, the end of our observation would be at week 48 after taf use. patients will receive regular follow up at week 4, 12, 24, 36 and 48 (for t-bil, ast, alt, creatinine, hbsag, hbv dna) till 1 year and the outcome will be collected. platelet and hbcrag would be examined at enrollment, 24 weeks and 48 weeks. hbeag and anti-hbeag will be examined at enrollment and 48 weeks.

Eligibility criteria:
inclusion criteria: * adult patients (age ≥20) with positive hbsag who are prepared to receive systemic chemotherapy * the presence of hbs antigen should be confirmed within recent two years * the patients who could receive systemic chemotherapy in 4 weeks exclusion criteria: * patients with poor performance status (zubrod-ecog ≥ 2 or karnofsky score ≤ 70) * patients with cirrhosis * patients had egfr lower than 15 ml/min/1.73m2 and didn't receive dialysis * patients had exposure to any nuc or interferon within 6 months before chemotherapy * patients were co-infected with hcv or hiv * allergy history to any tenofovir-based medication * pregnant woman * unable to sign inform consent

Keywords: taf cancer patients chemotherapy
effects of breathing and attention training (bat) on pain modulation

Conditions: Fibromyalgia

Summary: the hypersensitivity of fibromyalgia is associated with abnormal pain modulation within the cns, but not with peripheral or central sensitization. many brain areas that contribute to modulation of pain are known, but their testing is complex and expensive. quantitative sensory testing is easier to perform and repeatable. therefore, it will be used to evaluate the effects of breathing attention training (bat) on the hypersensitivity of fm participants. bat is a form of mindfulness meditation shown to decrease fm symptoms and possibly pain sensitivity. we hypothesize that pain modulation of chronic pain patients is improved by bat.


Eligibility criteria:
inclusion criteria: * individuals diagnosed with fibromyalgia will have pain of duration \> 6 months and meeting the 1990 research diagnostic criteria for fm (acr) * healthy, pain-free age matched controls without chronic pain exclusion criteria: * personal or family history of photosensitive epilepsy * prior history of cancer or diabetes * patients must be willing to discontinue their analgesics, hypnotics, anxiolytics, or anti-depressants during the study period for at least 5 half-lives.
the influence of expectations on patient satisfaction in the pediatric emergency department

Conditions: Patient Satisfaction

Summary: the purpose of this study is to determine whether physician knowledge of parental pre-visit expectations improves patient satisfaction in the pediatric emergency department.


Eligibility criteria:
inclusion criteria: * parent of child less than or equal to 18 years of age exclusion criteria: * inability to understand the english language surveys

Keywords: patient satisfaction patient expectations pediatric emergency department
cognition in patients with hypoglycemia, without diabetes

Conditions: Hypoglycemia; Cognition

Summary: the purpose of this study is to determine if there are differences in cognitive function (thinking) in individuals who have recurrent hypoglycemia (low blood sugars) following roux-en-y gastric bypass, compared with individuals who have also had a roux-en-y gastric bypass but do not have hypoglycemia.

this study will test the hypothesis that a history of recurrent hypoglycemia following gastric bypass is associated with differences in cognition (thinking), by analyzing results of cognitive testing in post-gastric bypass individuals with a history of hypoglycemia as compared to those without known hypoglycemia. this pilot study will identify cognitive domains of interest, as well as inform the development of a future battery of assessments, which could be replicated in a larger sample. cognitive domains which will be assessed include: premorbid intelligence, memory, language, executive function, and psychomotor speed.

Eligibility criteria:
inclusion criteria: 1. age 18-70 years of age, inclusive, at screening. 2. willingness to provide informed consent and attend one study visit. 3. for hypoglycemia after upper gi surgery group: males or females diagnosed with ongoing post upper gi surgery hypoglycemia, with prior episodes of neuroglycopenia, unresponsive to dietary intervention. 4. for hypoglycemia without a history of upper gastrointestinal surgery group: males or females diagnosed with ongoing hypoglycemia with prior episodes of neuroglycopenia, and without a history of prediabetes, diabetes, or upper gi surgery. 5. for post-bariatric without hypoglycemia group: males or females with history of bariatric surgery, and no history of symptomatic hypoglycemia. 6. for non-surgical controls only: males or females with no history of upper gi surgery and no history of hypoglycemia, prediabetes, or diabetes. exclusion criteria: 1. active treatment with any diabetes medications, except for acarbose. 2. history of cerebrovascular accident. 3. history of a traumatic brain injury not related to hypoglycemia. 4. active depression. 5. active alcohol abuse or substance abuse. 6. known insulinoma, gastrinoma or other neuroendocrine tumor. 7. having undergone same / similar cognitive assessments within the last calendar year. there will be no involvement of special vulnerable populations such as fetuses, neonates, pregnant women, children, prisoners, institutionalized or incarcerated individuals, or others who may be considered vulnerable populations.

Keywords: executive function memory post-bariatric hypoglycemia
efficacy and safety of diosmin 600mg versus placebo on painful symptomatology in patients with chronic venous disease of lower limbs

Conditions: Chronic Venous Disease of Lower Limbs

Summary: diosmin has a well established use status in improvement of the symptoms of venolymphatic insufficiency: heavy legs, pain, primo-decubitus restlessness and as complement treatment of capillary fragility. nevertheless, diosmin 600 mg did not benefit from a rigorous clinical study versus placebo, to establish its efficacy in the pain relief in chronic venous disease (cvd). the aim of this project led by dr. guex is to evaluate the efficacy and safety of diosmin 600 mg - diovenor® on the painful symptoms of cvd of the lower limbs, in a multicentre, controlled, randomised, double blind, placebo-controlled, parallel-group study.


Eligibility criteria:
inclusion criteria: 1. patient, man or woman, aged 18 and over, 2. patient presenting a c1s or c2s venous disease grade of the lower limbs 3. patient presenting a painful venous symptomatology in the lower limbs for at least 15 days. 4. patient suffering from venous symptomatology in one leg with a painful symptom intensity higher or equal to 30 mm (vas= 100mm) exclusion criteria: 1. patient treated by venotonic treatments or vascular protectants or assimilated dietary supplements or homeopathic treatments or diuretics within 15 days prior inclusion, 2. patients who started treatments such as calcium inhibitors, beta-blockers, angiotensin converting enzyme inhibitors and/or vasodilators and/or vasoconstrictors within 28 days prior inclusion (for patients already taking this type of treatments, dosage should not have been changed in the 28 days prior inclusion and should not be planned to change in the course of the study), 3. patient treated by any analgesic within 7 days prior inclusion, 4. patient treated by an anti-inflammatory treatment within 7 days prior inclusion, 5. patient using elastic venous compression 6. patient presenting permanent oedema, 7. patients presenting venous skin changes, 8. patient whose activity in the 4 following weeks (that is to say during the study) would be different from his/her usual activities (before the study), 9. patient suffering from a pathology generating other pains than venous pains in the lower limbs, 10. patient with a history of lower limbs trauma responsible for sequel pains, 11. patient with a known deep venous reflux, 12. patient with a history of venous thromboses or thrombo-embolic diseases within the last 6 months before inclusion, 13. patient treated with analgesics or anti-inflammatory treatments used as analgesics within 4 weeks prior inclusion 14. patient having a known hypersensitivity to diosmin or one of the excipients 15. patients with rare hereditary problems of galactose intolerance, the lapp lactase deficiency or glucose-galactose malabsorption ),
co-administration of acetaminophen with ibuprofen to improve duct-related outcomes in extremely premature infants

Conditions: Patent Ductus Arteriosus After Premature Birth

Summary: patent ductus arteriosus (pda), the most common cardiovascular complication of prematurity, is associated with higher mortality and morbidities in extremely low gestational age neonates (elgans, \ 60% elgans. treatment failure is associated with worsening rates of mortality and bronchopulmonary dysplasia (bpd), while early treatment success can achieve rates comparable to neonates without pda. treatment failure resulting in prolonged disease exposure is thought to be a major contributor. recently, combination therapy with acetaminophen and ibuprofen has emerged as a new treatment regime. acetaminophen exerts anti-prostaglandin effect through a different receptor site than ibuprofen, providing a biological rationale for their synergistic action. the objective of this study is to evaluate the clinical impact, efficacy and safety of combination regime (ibuprofen + iv acetaminophen) for the first treatment course for pda in elgans vs. ibuprofen alone (current standard treatment).


Eligibility criteria:
inclusion criteria: * preterm infants born \<27+0 weeks gestational age * permission given by the attending clinician to approach and then consent obtained from parents * diagnosis of pda ≥ 1.5 mm on echocardiography with unrestrictive predominantly left to right shunt * designated to receive first treatment course with intravenous or enteral ibuprofen, as decided by the attending team. exclusion criteria: * chromosomal anomaly * pre-treatment renal dysfunction defined as urine output \ 100 micromol/l * pre-treatment hepatic dysfunction defined as serum aminotransferase (alt) \> 100 units/l94 * platelet count \<50,000 per microliter * permission denied by the attending clinician to approach parents * parental consent not available * previous exposure to pda medical treatment with any drug (prophylactic indomethacin use for prevention of intraventricular hemorrhage will not be considered as pda treatment).

Keywords: preterm neonates patent ductus arteriosus echocardiography acetaminophen ibuprofen